Early response of XXXX to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy.

@entity1 @entity5 @entity7748 @entity1877 @entity74 @entity99
PURPOSE: The objective of our study was to determine the usefulness of the diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy (H- @entity7748 ) of @entity99 for the assessment of response to locoregional treatment. METHODS: Forty-four @entity1 (29 @entity1 ; mean age, 58 years) with @entity99 were treated locally. Magnetic resonance imaging examinations obtained before and at 1 and 6 months after transarterial chemoembolization were analyzed retrospectively. Imaging criteria included change in @entity5 size, percentage of enhancement in the arterial and portal venous phases, diffusion-weighted magnetic resonance imaging apparent diffusion coefficients, and @entity1877 concentration by quantitative H- @entity7748 . Response to treatment was grouped according to RECIST (Response Evaluation Criteria in @entity5 ) and European Association for the Study of the Liver (EASL) criteria based on magnetic resonance imaging at 6 months after treatment. Statistical analysis used paired t test, Fisher exact test, and univariate and multivariate Cox proportional hazards models. RESULTS: Before treatment, the median @entity5 diameter was 6 cm; at 6 months after treatment, median @entity5 diameter was 5.1 cm. According to RECIST and EASL, 66% of the @entity1 achieved partial response, 31% had stable disease, and 3% of the @entity1 showed @entity74 . One month after transarterial chemoembolization, apparent diffusion coefficient increased (P < 0.14), and mean @entity1877 concentration of the @entity5 decreased (P < 0.008). CONCLUSIONS: Diffusion-weighted imaging and hepatic @entity1877 levels by H- @entity7748 could predict response to locoregional therapy.
